IDH1

IDH1 Informations sur la molécule

Nom anglais	Isocitrate dehydrogenase [NADP] cytoplasmic	Nombre de médicaments commercialisés	3
Nombre de médicaments cliniques	11	Alias de la cible	IDH，EC 1.1.1.42，PICD，IDCD，Isocitrate Dehydrogenase (NADP(+)) 1，Isocitrate Dehydrogenase 1 (NADP+)， Soluble，HEL-S-26，IDH1，Isocitrate Dehydrogenase (NADP(+)) 1， Cytosolic，HEL-216，NADP(+)-Specific ICDH，Cytosolic NADP-Isocitrate Dehydrogenase，IDP，NADP-Dependent Isocitrate Dehydrogenase， Cytosolic，Oxalosuccinate Decarboxylase，Epididymis Secretory Protein Li 26，Isocitrate Dehydrogenase 1 (NADP+)，NADP-Dependent Isocitrate Dehydrogenase， Peroxisomal，IDPC，EC:1.1.1.42，Epididymis Luminal Protein 216，Epididymis Secretory Sperm Binding Protein，Isocitrate Dehydrogenase [NADP] Cytoplasmic
Phase de R&D la plus avancée	Approved

Nom anglais	Isocitrate dehydrogenase [NADP] cytoplasmic
Alias de la cible	IDH，EC 1.1.1.42，PICD，IDCD，Isocitrate Dehydrogenase (NADP(+)) 1，Isocitrate Dehydrogenase 1 (NADP+)， Soluble，HEL-S-26，IDH1，Isocitrate Dehydrogenase (NADP(+)) 1， Cytosolic，HEL-216，NADP(+)-Specific ICDH，Cytosolic NADP-Isocitrate Dehydrogenase，IDP，NADP-Dependent Isocitrate Dehydrogenase， Cytosolic，Oxalosuccinate Decarboxylase，Epididymis Secretory Protein Li 26，Isocitrate Dehydrogenase 1 (NADP+)，NADP-Dependent Isocitrate Dehydrogenase， Peroxisomal，IDPC，EC:1.1.1.42，Epididymis Luminal Protein 216，Epididymis Secretory Sperm Binding Protein，Isocitrate Dehydrogenase [NADP] Cytoplasmic
Nombre de médicaments commercialisés	3
Nombre de médicaments cliniques	11
Phase de R&D la plus avancée	Approved

IDH1 Liste de produits

Attribut
Protein (2)
Bibliothèque de produits
En ligne (2)
Espèces
Human (2)
Étiquette
His Tag (2)
Marqueur
Unconjugated (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
ID1-H51H6	Human	E. coli	Human IDH1 Protein, His Tag (active enzyme, MALS verified)				Ajouter au panier
ID1-H51H8	Human	E. coli	Human IDH1 (R132C) Protein, His Tag (MALS verified)				Ajouter au panier

Quantité totale2

IDH1Contexte de la molécule

The IDH enzymes catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), producing nicotinamide adenine dinucleotide phosphate (NADPH) in the process via the citric acid cycle. Eukaryotic cells express two distinct classes of IDHs that utilize either NAD or NADP as their cofactors and serve diverse biological functions. NAD-dependent IDH is localized to the mitochondrial matrix and is well known for its central role for energy production in the Krebs cycle. NADP-dependent IDHs are primarily located either in mitochondria or cytoplasm . Each NADP-dependent isozyme is a homodimer. Mutations of Arg132 of human IDH1 result in a reduced ability of the enzyme to convert isocitrate to alpha ‑ketoglutarate, but the enzyme acquires the ability to generate 2-hydroxyglutarate (2HG) from alpha‑ketoglutarate，2-HG is elevated in several tumor types, including a subset of AMLs.

IDH1Alias de la molécule

IDH1,PICD,IDP

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Safusidenib	DS-1001b; DS-1001; AB-218	Phase 3 Clinical	Daiichi Sankyo Co Ltd	Astrocytoma; Biliary Tract Neoplasms; Glioblastoma; Glioma; Oligodendroglioma; Solid tumours	Details
Ranosidenib	HMPL-306	Phase 3 Clinical		Glioma; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Solid tumours	Details
TQB-3454	TQB-3454; CT-2755	Phase 3 Clinical	Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd	Bile Duct Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Solid tumours	Details
MT-001	MT-001; MT001	Phase 2 Clinical	Zhejiang Meton Pharmaceutical Co Ltd	Neoplasms; Solid tumours	Details
BAY-1436032	BAY-1436032	Phase 1 Clinical	Bayer AG	Leukemia, Myeloid, Acute; Solid tumours	Details
IDH-305	IDH-305	Phase 1 Clinical	Novartis Pharma Ag	Glioma; Leukemia, Myeloid, Acute; Neoplasms	Details
IDH1/2 inhibitor (Eli Lilly)		Phase 1 Clinical	Eli Lilly And Company	Neoplasms	Details
BPI-221351	BPI-221351	Phase 1 Clinical	Betta Pharmaceuticals Co Ltd	Glioma; Solid tumours	Details
KY-100001	KY-100001	Phase 1 Clinical	Kpc Pharmaceuticals Inc	Solid tumours	Details
HH-2301	HH-2301; HH2301	Phase 1 Clinical	ShangHai HaiHe Biopharma Co Ltd	Biliary Tract Neoplasms; Chondrosarcoma; Glioma; Solid tumours	Details
LY-3410738	LY-3410738	Phase 1 Clinical	Eli Lilly And Company	Cholangiocarcinoma; Chondrosarcoma; Glioma; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Solid tumours	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Ivosidenib	CS-3010; S-95031; CS 3010; AG-120	Approved	Agios Pharmaceuticals Inc	拓舒沃, Tidhesco, Tibsovo, TIBSOVO, Tuoshuvo, Tosuvo	United States	Leukemia, Myeloid, Acute	Servier Pharmaceuticals Llc	2018-07-20	Bile Duct Neoplasms; Cholangiocarcinoma; Chondrosarcoma; Ependymoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Hepatoblastoma; Histiocytosis, Langerhans-Cell; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Medulloblastoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Sarcoma, Myeloid; Solid tumours; Wilms Tumor	Details
Vorasidenib	AG-881; AGI-23088; S-95032; S95032	Approved	Agios Pharmaceuticals Inc	VORANIGO	United States	Astrocytoma; Oligodendroglioma; Glioma	Servier Pharmaceuticals Llc, Laboratoires Servier	2024-08-06	Astrocytoma; Ganglioglioma; Glioblastoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Liver Diseases; Liver Dysfunction; Myelodysplastic Syndromes; Oligodendroglioma	Details
Olutasidenib	FT-2102	Approved	Forma Therapeutics Holdings Inc	Rezlidhia	United States	Leukemia, Myeloid, Acute	Rigel Pharmaceuticals Inc	2022-12-01	Chondrosarcoma; Diarrhea; Irritable Bowel Syndrome; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes	Details